AI assistant
Innoviva, Inc. — Director's Dealing 2011
Aug 3, 2011
32090_dirs_2011-08-03_a8b45477-4347-4531-b0c2-26bdca93deb4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: THERAVANCE INC (THRX)
CIK: 0001080014
Period of Report: 2011-08-02
Reporting Person: GLAXOSMITHKLINE PLC (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2011-08-02 | Common Stock | P | 102466 | $19.71 | Acquired | 15667542 | Indirect |
Footnotes
F1: Common stock purchased pursuant to the right of GlaxoSmithKline LLC ("GSK LLC") under Section 2.1(d)(ii) of the Amended and Restated Governance Agreement by and among Theravance, Inc. (the "Issuer"), GSK LLC and GlaxoSmithKline plc dated as of June 4, 2004, as amended. Pursuant to Section 2.1(d)(ii), GSK LLC has the right to purchase from the Issuer, on a quarterly basis, sufficient shares of common stock to maintain its ownership percentage in the Issuer taking into account the preceding quarter's option exercise and equity vesting activity.
F2: Shares of Common Stock are held of record by Glaxo Group Limited and GSK LLC.